Virginia is currently home to 1821 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432
Recruiting
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: NEXT Oncology, Fairfax, Virginia
Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Register for Updates
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
NCT06472661
Recruiting
This study is for adult patients with advanced melanoma who are receiving immunotherapy and who are planning on having surgery for their cancer. All participants in this study will receive an experimental treatment made up of focused ultrasound ablation (FUSA), a non-invasive experimental treatment that uses ultrasound waves to heat and destroy tumor tissue, and an injection in the tumor with an experimental drug that activates the immune system called polyICLC (polyinosinic-polycytidylic acid t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Advanced Melanoma
Register for Updates
Prospective Evaluation of Infectious Vulvovaginitis on Wound Complication Rates After Vulvar Excision for Premalignant Lesions
NCT06070454
Recruiting
Primary: * To measure the rate of perioperative vulvovaginitis in a population of patients in central VA with non-malignant vulvar disease who require surgical excision * To correlate the rate of vulvovaginitis with rate of wound cellulitis and incisional breakdown in patients undergoing SPV/WLE for vulvar disease We will use a vulvovaginal swab to test for the most common causes of vulvovaginitis - bacterial vaginosis (BV), trichomonas, and candida. The swab will be collected preoperatively on... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Vaginitis, Vulvar Diseases
Register for Updates
Effectiveness of Remote Foot Temperature Monitoring
NCT05728411
Recruiting
Diabetic foot ulcers are common, debilitating, and costly complications of diabetes, disproportionately impacting Black and rural Veterans. Forty percent of individuals have an ulcer recurrence within a year of ulcer healing and 65% within 5 years. Monitoring plantar foot temperatures is one of the few interventions that reduces the risk of ulcer recurrence. Despite the evidence, adoption has been poor because the original procedures, including the use of handheld thermometers, were burdensome a... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
09/11/2024
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia
Conditions: Diabetic Foot
Register for Updates
A Study to Assess the Efficacy and Safety of HMI-115 in Subjects with Endometriosis-Associated Pain
NCT05101317
Recruiting
This study is designed to evaluate the safety and efficacy of HMI-115 compared to placebo over a 12 weeks period on subjects with moderate to severe endometriosis-associated pain.
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
09/11/2024
Locations: Tidewater Clinical Research/TPW, Norfolk, Virginia
Conditions: Endometriosis
Register for Updates
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
NCT04471909
Recruiting
Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: Sentara Norfolk General Hospital, Norfolk, Virginia
Conditions: Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
Register for Updates
Loss of Y Chromosome in Aortic Stenosis
NCT06595407
Recruiting
The most common heart valve disease in humans is aortic stenosis which is a critical narrowing of the valve through which the heart has to pump blood to the rest of the body. This condition occurs in 2-3% of adults over 65 years of age and when it progresses to a severe stage leads to heart failure and need for valve replacement procedures (including surgery and catheter-based replacement). Aortic stenosis has a strong male predominance. The purpose of this study is to evaluate whether loss of Y... Read More
Gender:
MALE
Ages:
40 years and above
Trial Updated:
09/10/2024
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Aortic Stenosis
Register for Updates
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
NCT06382168
Recruiting
This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP-10917 is given as a 14-day continuous IV infusion every 28 days, alongside a 14-day oral course of venetoclax following an initial dose ramp-up. The initial phase tests a starting dose of 4 mg/m²/day of DFP-10917 with 400 mg daily of venetoclax. The Data Monitoring Committee reviews toxicity after one treatment cycle. If DLTs are minimal,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: University of Virginia Cancer Center, Charlottesville, Virginia
Conditions: Leukemia, Myeloid, Acute
Register for Updates
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
NCT05446272
Recruiting
DIVA is a pragmatic randomized clinical trial (RCT) to determine: among (P) preterm infants born 23 0/7-28 6/7 weeks gestation undergoing extubation from mechanical ventilation, whether (I) Non-invasive neurally adjusted ventilatory assist (NIV-NAVA) (C) compared with Non-synchronized nasal intermittent positive pressure ventilation (NS-NIPPV), will reduce the incidence of (O) extubation failure within (T) 5 days (120 hours) of extubation.
Gender:
ALL
Ages:
Between 0 days and 9 weeks
Trial Updated:
09/09/2024
Locations: Children's Hospital of Richmond, Richmond, Virginia
Conditions: Extubation Failure, Bronchopulmonary Dysplasia, Death
Register for Updates
Immune Registry for Organ Transplantation From COVID Positive Donors.
NCT05595837
Recruiting
The purpose of this study is to collect data generated by standard clinical practice to determine the short term and long term clinical outcomes of recipients of solid organ transplantation from COVID-19 infected donors and compare it to recipients with organ transplant from COVID-19 negative donors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/06/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: COVID-19, Organ Transplant
Register for Updates
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
NCT06106360
Recruiting
A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2024
Locations: Inova Schar Cancer Institute, Fairfax, Virginia
Conditions: Solid Tumor, Hematological Malignancy
Register for Updates
A Study of Evorpacept (ALX148) in Patients with Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127
Recruiting
A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2024
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Register for Updates